Deloitte sees a major shakeup going on in clinical research strategies at the large pharma companies. Instead of focusing on the development of a small portfolio of blockbuster meds, pharma pipelines are shifting to create a host of new therapies that will have higher efficacy in smaller groups--the genotype-basing approach that's been so much discussed in biotechnology. Report